AGEN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
|Holder||Position||Shares||% of Shares |
|Dr. Garo H Armen PhD||Chairman & CEO||1,051,228||1.24%||2015-12-28|
|Chadarevian Gamil De||N/A||88,610||0.1%||2006-02-28|
|Mr. John N. Hatsopoulos||Director||65,000||less than 0.1%||2009-02-25|
|Kerry Wentworth||VP, Clinical, Reg & Qual||57,410||less than 0.1%||2014-02-26|
|Karen Valentine||VP General Counsel||51,534||less than 0.1%||2014-01-23|
|Christine Klaskin||VP, Finance||23,690||less than 0.1%||2013-01-28|
|Ozer Baysal||Chief Business Officer||21,850||less than 0.1%||2016-01-04|
|Margaret M. Eisen||N/A||20,000||less than 0.1%||2008-05-16|
|Dr. Hyam I. Levitsky,M.D.||N/A||15,376||less than 0.1%||2009-02-27|
|Insider||Position||Date||Buy/Sell||Shares||Shares Owned Following This (Direct & Indirect)||Trade Price ($)||Cost ($1000)||Price Change
Since Trade (%)
|Share Ownership Details|
|ARMEN GARO H||Chairman & CEO|
(Click for the stocks that their CEOs have bought)
220,349 (by Trust and Antigenics Holdings)
|ARMEN GARO H||Chairman & CEO||2015-09-25||Buy||100,000||1,713,653||$5.03||503||-45.92||1,409,607 (Direct)|
304,046 (by Trust and Antigenics Holdings)
|Ballantyne Charles Evan||CFO||2015-09-25||Buy||10,000||10,000||$5.05||50.5||-46.14||10,000 (Direct)|
0 (see footnote)
|QVT Associates GP LLC||10% Owner||2015-01-09||Sell||2,343,630||6,915,630||$5.31||12444.7||-48.78|
6,915,630 (Through QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P.)
|Wentworth Kerry||VP, Clinical, Reg & Qual||2014-02-26||Sell||5,000||57,410||$5||25||-45.6||57,410 (Direct)|
|Valentine Karen||VP General Counsel||2014-01-23||Sell||2,850||51,534||$3.5||10||-22.29||51,534 (Direct)|
|Sharp Shalini||Director||2013-01-30||Sell||288||81,311||$4.36||1.3||-37.61||81,311 (Direct)|
|Sharp Shalini||Director||2012-10-31||Sell||288||80,974||$4.4||1.3||-38.18||80,974 (Direct)|
|Sharp Shalini||Director||2012-08-29||Sell||288||76,602||$4.64||1.3||-41.38||76,602 (Direct)|
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as Conversion of derivative security or Exercise of Options are not included. Insiders are only limited to Officers and/or Directors of the company.
"Shares" change (fifth column) and "Shares Owned Following This (Direct & Indirect)" transactions (sixth column) are split adjusted. The "Share Ownership Details" (last column) displayed data is as of reported.